Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs 10X Genomics Inc (TXG) Price & Performance

iShares MSCI Taiwan ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs 10X Genomics Inc — how do they compare? iShares MSCI Taiwan ETF trades at $105.6, while 10X Genomics Inc trades at $58.6 (market cap $7.64B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares MSCI Taiwan ETF nearer its low. Which is the better fit depends on your goals.

EWTTXG
Sector
Broad Market / FactorHealth
52-Week High
$111.53$58.57
52-Week Low
$58.05$11.34
Market Cap
$7.64B
Enterprise Value
$7.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

EWT, the iShares MSCI Taiwan ETF, trades at $103.09, up 1.09% today, with a bullish technical signal driven by strong moving average alignment. Recent news highlights Taiwan's market outperformance, fueled by AI-driven semiconductor demand, with the ETF gaining over 60% year-to-date. Key support lies at $102, while resistance is at $104. The RSI_6 at 96.58 indicates overbought conditions, suggesting potential near-term consolidation.

The outlook remains positive due to Taiwan's critical role in the global semiconductor supply chain, though risks include geopolitical tensions with China and dependency on AI sector momentum. Analysts are bullish given the ETF's exposure to top performers like TSMC, but investors should monitor any shifts in foreign capital flows and semiconductor cycle dynamics.

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG